Document is current
Any future updates will be listed below
-
Authors
Razavi, Peyman https://orcid.org/0000-0002-2650-152X
Baldwin, Grace https://orcid.org/0000-0001-9872-6974
Vingopoulos, Filippos https://orcid.org/0000-0003-3778-5473
Garg, Itika https://orcid.org/0000-0002-9537-8561
Tracy, Jack https://orcid.org/0009-0001-4132-391X
Wescott, Hannah https://orcid.org/0000-0002-0962-0316
Choi, Hanna https://orcid.org/0000-0003-4966-5321
Zeng, Rebecca https://orcid.org/0000-0002-1186-4758
Lains, Ines
Husain, Deeba https://orcid.org/0000-0002-8494-0950
Kim, Leo A. https://orcid.org/0000-0001-9106-6416
Vavvas, Demetrios G. https://orcid.org/0000-0002-8622-6478
Miller, John B. https://orcid.org/0000-0003-0109-9738
- License Information
-
More Information
Article History
Received: 8 May 2023
Revised: 20 September 2023
Accepted: 19 October 2023
First Online: 13 November 2023
Declarations
:
: The study was conducted in accordance with the tenets set forth in the Declaration of Helsinki and all necessary authorizations were obtained from the MEE Institutional Review Board (Protocol #: 2019P001863). Written informed consent was obtained from all participants prior to the inclusion in this study.
: Not required.
: D.H. is a consultant for Allergen, Genetech, and Omeicos Therapeutics and has received financial support from National Eye Institute, Lions VisionGift, Commonwealth Grant, Lions International, Syneos LLC, and the Macular Society. L.A.K. has received research support from National Eye Institute (R01EY027739), Deparment of Defense (W81XWH1910824), CureVac AG, and INGENIA Therapeutics and has a financial arrangement with Pykus Therapeutics. D.G.V. has served on the Scientific Advisory Board for Olix and Valitor, has been an advisor to Drusolv, and is an inventor on patents of Neuroprotection held by Mass Eye and Ear. J.B.M. is a consultant for Alcon, Allergan, Topcon, Carl Zeiss, Sunovion, and Genentech.
: This funding organization had no role in the design or conduct of this research.
